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potential risk of neurological damage generally mandates 
prompt discontinuation of OKT3. 
The mechanism of OKT3-induced encephalopathy is unclear. 
OKT3 may crossreact with surface antigens shared by both 
lymphocytes and cells of the central nervous system (5). Alter-
natively, the cytokines released by OKT3 may disrupt neuroen-
docrine functions (6). In addition, our recent practice of ad-
ministering indomethacin concomitantly with OKT3 to prevent 
first-dose reactions to OKT3 may have played a contributory 
role. Since October 1989. four episodes of encephalopathy (pa-
tients 3-6) have been observed in 55 renal transplant patients 
who have received indomethacin 50 mg orally or rectally q. 6-
8 hr for 48-72 hr after initiation of OKT3 treatment. This 
corresponds to a prevalence of 7.3%. In comparison, only 2 
episodes of encephalopathy (patients 1 and 2) had been ob-
served among 173 patients who received OKT3 without indo-
methacin between January 1987 and December 1989 (incidence 
1.2%, P<0.05). In earlier studies, indomethacin has been asso-
ciated with various central nervous system side-effects such as 
somnolence, feelings of dissociation, paranoia, and even psy-
chosis ( 7-10). Concurrent administration of indomethacin may 
further enhance the propensity to develop encephalopathic 
complications in patients receiving OKT3. perhaps especially 
in the presence of ongoing acute allograft rejection (1 ). Further 
postmarketing studies are required to clarify the pharmaco-
epidemiology of this drug-induced syndrome. A high index of 
suspicion of this adverse reaction should be maintained when 
encephalopathic or psychotic episodes develop in patients re-
ceiving OKT3. 
GARY L. CHAN' 
SAMUEL S. WEINSTEIN2 
CHARLES E. WRIGHT2 
VICTOR D. BOWERS3 
DENISE Y. ALVERANGA2 
DANA L. SHIRES< 
JOHN R. ACKERMANN'l 
WILLIAM W. LEFOR" 
LAWRENCE KAHANA2 
The Department of Pharmacotherapy and Research 
The Renal Transplant Service 
Tampa General Hospital 
The Departments of Internal Medicine and Surgery 
College of Medicine 
University of South Florida 
Tampa, Florida 
'Department of Pharmacotherapy and Research, Tampa General 
Hospital. 
2 Department of Internal Medicine, College of Medicine, University 
of South Florida. 
3 Department of Surgery, College of Medicine, University of South 
Florida. 
REFERENCES 
1. Gross ML, Pearson RM, Kennedy J, Moorhead JF, Sweny P. 
Rejection encephalopathy. Lancet 1982; 2: 1217. 
2. Martin MA, Massanari M, Nghiem DD, Smith JL, Corry RJ. 
Nosocomial aseptic meningitis associated with administration of 
OKT3. JAMA 1988; 259: 2002. 
3. Emmons C. Smith J. Flanigan M. Cerebrospinal fluid inflammation 
during OKT3 therapy. Lancet 1986; 2: 510. 
4. Roden J, Klintmalm GBG, Husberg BS, Nery J, Olson LM. Cere-
brospinal fluid inflammation during OKT3 therapy. Lancet 1987; 
2: 272. 
5. Williams AF, Gagnon J. Neuronal cell Thy-1 glycoprotein: homol-
ogy with immunoglobulin. Science 1982; 216: 696. 
6. Dinarello CA, Mier JW. Lymphokines. N Engl J Med 1987; 317: 
940. 
7. Gotz V. Paranoid psychosis with indomethacin. Br Med J 1978; 1: 
49. 
8. Carney MWP. Paranoid psychosis with indomethacin. Br Med J 
1977; 2: 994. 
9. Rothermich NO. Deafness and hand tremor with indomethacin. 
JAMA 1973; 12: 1471. 
10. Rothermich NO. An extended study of indomethacin. JAMA 1966: 
195: 123. 
Received 4 October 1990. 
Accepted 3 December 1990. 
ESOPHAGEAL COMPLICATIONS IN ORTHOTOPIC LIVER TRANSPLANT PATIENTS' 
Although serious esophageal complications are not uncom-
mon after liver transplantation, these have received little at-
tention in the literature (1). We report here the nature and 
treatment of major esophageal complications encountered in 7 
(0.6%) of 1154 adult liver transplant recipients at the Univer-
sity of Pittsburgh between January 1, 1986 and March 31, 1990. 
Of 4 perforations of the distal esophagus (Table 1), 3 were 
thought in retrospect to have been caused by pretransplant 
sclerotherapy. The complication in 2 recipients was diagnosed 
one or 2 days posttransplantation, and in a third at the time of 
liver replacement. The fourth perforation was secondary to 
multiple hemostatic sutures placed during transplantation near 
the esophagogastric junction. Two patients had intractable 
esophageal bleeding from multiple ulcerations caused by cyto-
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Institutes of Health. Bethesda, MD. 
megalovirus and one patient with an Epstein-Barr virus infec-
tion developed an esophageal clonal B cell lymphoma. 
The treatment for the 7 patients is summarized in Table 1. 
Three of the 4 patients with esophageal perforation died from 
2 to 198 days after the diagnosis in spite of treatment with 
thoracic and/or transabdominal drainage, exclusion by tempo-
rary ligation of the lower esophagus, or an attempt at esopha-
gectomy and colon interposition. The single survivor closed his 
perforation spontaneously after cervical esophagostomy and 
prolonged SUbdiaphragmatic drainage. 
One of the 2 patients with massive bleeding survived after 
total esophagectomy and colon interposition 5 months later. 
The other died of multiple bacterial infections and dissemi-
nated tuberculosis 2 months after the hemorrhage was con-
trolled with suture ligation of multiple bleeding sites through a 
longitudinal esophagostomy, cervical esophagostomy, tube gas-
trostomy, and temporary ligation of the esophagus at the esoph-
agogastric junction. The patient with lymphoma had regression 
of the lesion when immunosuppression was reduced, but hepatic 
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TABLE 1. University of Pittsburgh results" 
Age Diagnosis OLTX date Complication diagnosis Treatment Hospital stay Outcome date (days) 
X.N. 31 CAH-B 6/4/88,6/9/88 Perf. 6/2/88 ex., ces., gs. 64 D 
G.J. 53 CAH-B 2/2/89 Perf. 2/20/89 ee., ces., gs. 19 D 
RA. 38 CAH-B 3/30/89 Perf. 4/6/89 1 ex., ces., js., 198 D 
2 ci. 
H.R 33 SBC 3/5/90 (also gas- Perf. 3/12/90 ces. 133 A 
trectomy) 
S.B. 53 CC 9/26/88 Bleed 11/3/88 1 esl., 2 ex., 99 D 
gs. 
M.A. 64 PBC 3/13/89 Bleed 4/7/89 1 ee., ces., 2 ci. 185 A 
B.J. 34 CAH-C 1/10/86,6/19/88 LPD 3/10/88 ege. 18 A 
" CAH, chronic active hepatitis due to B (-B) or C (-C) virus; PBC, primary biliary cirrhosis; SBC, secondary biliary cirrhosis; CC, cryptogenic 
cirrhosis; ex .. exclusion; ces., cervical esophagostomy; gs., gastrostomy; ee., esophagectomy; js., jejunostomy; cl., colon interposition; esl., 
esophagectomy with suture ligation; ege., esophagogastrectomy; Perf., perforation; LPD, lymphoproliferative disorder (B cell lymphoma). 
rejection followed, necessitating retransplantation. He then had 
a recurrence of the lesion that was treated with esophagogas-
trectomy. Five months later, the lymphoma recurred above the 
suture line, but this regressed after cyclosporine was stopped 
and treatment was started once-and subsequently twice-per 
week with the new immunosuppressive agent FK506 (2, 3). He 
now is tumor-free almost 3 years after the first liver transplan-
tation, 18 months after retransplantation and 8 months after 
the change in immunosuppression. 
An obvious conclusion from these observations is that major 
esophageal complications in the transplant population have a 
very high morbidity and mortality. Aside from the added burden 
of immunosuppression, liver transplant patients are particu-
larly vulnerable because of their general disability from liver 
failure, the frequent involvement of the esophagus secondary 
to liver disease, and the consequent high rate of endoscopy in 
the days or weeks preceding transplantation. Furthermore, it 
is obvious that pretransplantation sclerotherapy for both treat-
ment of bleeding esophageal varices and prophylaxis does carry 
a certain risk of perforation of the esophagus (4, 5), which may 
not be diagnosed, as in 2 of our patients, until after transplan-
tation. After sclerotherapy, a high degree of suspicion is nec-
essary in order to rapidly diagnose any possible perforation. 
When sepsis or bleeding were controlled with effective drainage 
or esophagectomy, later reconstruction and esophageal replace-
ment was possible in one case. In another patient with esoph-
ageal lymphoma, a radical esophagogastrectomy and primary 
reconstruction were performed without incident. 
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COMBINATION THERAPY WITH GANCICLOVIR AND INTRAVENOUS IgG FOR CYTOMEGALOVIRUS 
INFECTIONS IN PEDIATRIC LIVER TRANSPLANT RECIPIENTS 
Successful liver transplantation and postoperative immuno-
suppression has produced a group of patients who are suscep-
tible to infections by opportunistic organisms. With the advent 
of more selective immunosuppressive techniques, we have noted 
a decrease in serious bacterial and fungal infections after liver 
transplantation. Viral infections, however, remain a significant 
cause of morbidity and mortality. Cytomegalovirus is the most 
common viral pathogen identified in opportunistic infections 
in transplant patients and has been implicated as the offending 
organism in 50% of all posttransplant infections (1). CMV 
infections can produce a variety of symptoms. Fever is the most 
common manifestation and may be the only clinical sign. 
Infection of the gastrointestinal tract is common and may 
produce vomiting, diarrhea, or G I bleeding. CMV infection of 
the transplanted liver can produce hepatitis that is difficult to 
distinguish from rejection. Pulmonary infection is the most 
dreaded form of the disease and has a mortality rate of up to 
85-90% (2). Traditionally, treatment of CMV infections after 
